Drug Trial Radar · NCT04516915
IMU-838 and Oseltamivir in the Treatment of COVID-19
Last checked: Nov 19, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 15, 2020
Primary completion
May 20, 2022
Study completion Sep 21, 2022
Sponsor
- Lead sponsor
- University Hospitals Coventry and Warwickshire NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Immunic AG; University of Warwick; MODEPHARMA
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)
Conditions
- Covid 19
Interventions
IMU-838Drug
IMU-838 twice daily at 22.5mg doses for 14 days
OseltamivirDrug
Oseltamivir twice daily at 75mg doses for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Coventry and Warwickshire NHS Trust
Coventry, West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.